After almost two decades with MSD, Ashraf Mallak, managing director for the company in the GCC region, dives into the often-overlooked healthcare capabilities of the Gulf countries, including the fact that certain products approved by the US FDA can sometimes be available in the region in as little as one week. Mallak also speaks about the bold efforts to maximize the use of data in the region, the performance and future of Keytruda, how Saudi has become a growth driver for the American giant, and exciting news regarding its upcoming COVID-19 treatment.
Most of the markets in the GCC are trying to adopt innovation as fast as possible, even faster than in big European countries in many cases. The authorities are involved in a healthy competition to be the first to provide innovative health solutions for their populations
